benfluorex has been researched along with Insulin Resistance in 15 studies
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 9.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
| "To evaluate the change in lipids and insulin sensitivity in 10 obese type II diabetic patients after treatment with benfluorex or placebo for 2 wk." | 9.07 | Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
| "We have examined the effect of chronic (20 days) oral administration of benfluorex (35 mg/kg) in a rat model of NIDDM, induced by injection of STZ 5 days after birth and characterized by frank hyperglycemia, hypoinsulinemia, and hepatic and peripheral insulin resistance." | 7.68 | Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats. ( Bailbe, D; Blondel, O; Portha, B; Serradas, P, 1993) |
| "3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 5.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
| "To evaluate the change in lipids and insulin sensitivity in 10 obese type II diabetic patients after treatment with benfluorex or placebo for 2 wk." | 5.07 | Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
| " Benfluorex treatment improves insulin sensitivity and has antihyperglycemic and hypolipidemic effects in human beings and in experimental animals." | 4.78 | [Mode of action of benfluorex. Recent data]. ( Brindley, DN, 1992) |
| "It has been reported that benfluorex ameliorates the insulin resistance induced by high-fat feeding when its administration is initiated at the same time as the change in diet." | 3.70 | Benfluorex improves muscle insulin responsiveness in middle-aged rats previously subjected to long-term high-fat feeding. ( Gumà, A; Muñoz, P; Palacín, M; Sevilla, L; Testar, X; Zorzano, A, 1999) |
| " Benfluorex has both anorectic and metabolic effects that lower body weight and improve insulin sensitivity in obesity and type 2 diabetes." | 3.69 | Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR:LA-cp rats. ( Amy, RM; Brindley, DN; Dolphin, PJ; Graham, SE; Russell, JC; Wood, GO, 1997) |
| "We have examined the effect of chronic (20 days) oral administration of benfluorex (35 mg/kg) in a rat model of NIDDM, induced by injection of STZ 5 days after birth and characterized by frank hyperglycemia, hypoinsulinemia, and hepatic and peripheral insulin resistance." | 3.68 | Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats. ( Bailbe, D; Blondel, O; Portha, B; Serradas, P, 1993) |
| "Benfluorex + insulin is a valid alternative for obese patients who remain poorly controlled despite insulin or who require high doses of insulin." | 2.69 | Added benfluorex in obese insulin-requiring type 2 diabetes. ( Bauduceau, B; Brun, JM; Guillon-Metz, F; Leutenegger, M; Martin, C; Nicolino-Peltier, C; Richard, JL; Vannereau, D, 1998) |
| "The relief of insulin resistance is one of the two therapeutic targets of the treatment of type 2 diabetes." | 2.40 | [Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs]. ( Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N, 1999) |
| "Benfluorex-treated animals showed significant decreases in glucose intolerance, hyperinsulinemia, hypertriglyceridemia, hypercholesterolemia, and plasma LDL- and VLDL-cholesterol, with no evidence of aortic atheroma." | 1.30 | Metabolic and anti-atherogenic effects of long-term benfluorex in dyslipidemic insulin-resistant sand rats (Psammomys obesus). ( Bennani, N; El Madani, T; Hadjiisky, P; Marquié, G; Pieraggi, MT; Ravel, D; Seguin, L; Solera, ML, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brindley, DN | 3 |
| Storlien, LH | 2 |
| Pan, DA | 2 |
| Kusunoki, M | 2 |
| Cooney, GJ | 1 |
| Lacour, F | 1 |
| Espinal, J | 1 |
| Arnaud, O | 1 |
| Duhault, J | 1 |
| Oakes, ND | 1 |
| Jenkins, AB | 1 |
| Serradas, P | 1 |
| Blondel, O | 1 |
| Bailbe, D | 1 |
| Portha, B | 1 |
| Bianchi, R | 1 |
| Bongers, V | 1 |
| Bravenboer, B | 1 |
| Erkelens, DW | 1 |
| Pontiroli, AE | 1 |
| Pacchioni, M | 1 |
| Piatti, PM | 1 |
| Cassisa, C | 1 |
| Camisasca, R | 1 |
| Pozza, G | 1 |
| Russell, JC | 1 |
| Graham, SE | 1 |
| Dolphin, PJ | 1 |
| Amy, RM | 1 |
| Wood, GO | 1 |
| Leutenegger, M | 1 |
| Bauduceau, B | 1 |
| Brun, JM | 1 |
| Guillon-Metz, F | 1 |
| Martin, C | 1 |
| Nicolino-Peltier, C | 1 |
| Richard, JL | 1 |
| Vannereau, D | 1 |
| Marquié, G | 1 |
| El Madani, T | 1 |
| Solera, ML | 1 |
| Pieraggi, MT | 1 |
| Hadjiisky, P | 1 |
| Ravel, D | 1 |
| Seguin, L | 1 |
| Bennani, N | 1 |
| Sevilla, L | 1 |
| Gumà, A | 1 |
| Muñoz, P | 1 |
| Testar, X | 1 |
| Palacín, M | 1 |
| Zorzano, A | 1 |
| Brogard, JM | 1 |
| Neyrolles, N | 1 |
| Andres, E | 1 |
| Blicklé, JF | 1 |
| Sodoyez, JC | 1 |
| Sodoyez-Goffaux, F | 1 |
4 reviews available for benfluorex and Insulin Resistance
| Article | Year |
|---|---|
Mechanisms for the effects of benfluorex on the obese-diabetic-dyslipidemic syndrome.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hyperlipidemias; Hypogl | 1993 |
Effects of benfluorex on in vivo patterns of insulin resistance induced by diets rich in fat or fructose.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Carbohydrates; Dietary Fa | 1993 |
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine | 1999 |
[Mode of action of benfluorex. Recent data].
Topics: Animals; Arteriosclerosis; Diabetes Mellitus, Type 2; Drug Interactions; Fatty Acids; Female; Fenflu | 1992 |
3 trials available for benfluorex and Insulin Resistance
| Article | Year |
|---|---|
Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients.
Topics: Apolipoprotein A-I; Apolipoproteins B; Appetite Depressants; Blood Glucose; C-Peptide; Cholesterol; | 1993 |
Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
Topics: 3-Hydroxybutyric Acid; Appetite Depressants; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mel | 1996 |
Added benfluorex in obese insulin-requiring type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mellitus | 1998 |
8 other studies available for benfluorex and Insulin Resistance
| Article | Year |
|---|---|
Insulin resistance, hyperinsulinemia and diabetes--contribution of benfluorex. Prague, 11 September 1992. Symposium proceedings.
Topics: Animals; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hyperinsulinism; Hypoglycemic Agents; Insu | 1993 |
Improvement in glucose tolerance of insulin resistant rats after chronic or acute administration of benfluorex.
Topics: Administration, Oral; Animals; Blood Glucose; Drug Administration Schedule; Fenfluramine; Glucose In | 1993 |
Syndromes of insulin resistance in the rat. Inducement by diet and amelioration with benfluorex.
Topics: Analysis of Variance; Animals; Diet; Dietary Carbohydrates; Dietary Fats; Disease Models, Animal; Fe | 1993 |
Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; Fenflura | 1993 |
Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR:LA-cp rats.
Topics: Animals; Arteriosclerosis; Fenfluramine; Hypolipidemic Agents; Insulin Resistance; Male; Obesity; Ra | 1997 |
Metabolic and anti-atherogenic effects of long-term benfluorex in dyslipidemic insulin-resistant sand rats (Psammomys obesus).
Topics: Animal Nutritional Physiological Phenomena; Animals; Aorta; Arteriosclerosis; Body Weight; Cholester | 1998 |
Benfluorex improves muscle insulin responsiveness in middle-aged rats previously subjected to long-term high-fat feeding.
Topics: Aging; Animals; Biological Transport; Blood Glucose; Blotting, Northern; Body Weight; Deoxyglucose; | 1999 |
[Effects of chronic administration of benfluorex on the pharmacokinetics of iodine 123 labelled insulin in Zucker obese rats (fa/fa)].
Topics: Administration, Oral; Animals; Fenfluramine; Hypolipidemic Agents; Insulin; Insulin Resistance; Iodi | 1992 |